CrowdStrike Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CrowdStrike Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $3.59B | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | $2.96B | Mar 5, 2026 |
| FY2026 | Jan 31, 2024 | $2.30B | Mar 5, 2026 |
| FY2024 | Jan 31, 2023 | $1.64B | Mar 10, 2025 |
| FY2023 | Jan 31, 2022 | $1.07B | Mar 7, 2024 |
| FY2022 | Jan 31, 2021 | $644.89M | Mar 9, 2023 |
| FY2022 | Jan 31, 2020 | $339.79M | Mar 16, 2022 |
| FY2021 | Jan 31, 2019 | $162.59M | Mar 18, 2021 |
| FY2020 | Jan 31, 2018 | $64.27M | Mar 23, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($162.50M) | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | ($15.24M) | Mar 5, 2026 |
| FY2026 | Jan 31, 2024 | $72.18M | Mar 5, 2026 |
| FY2024 | Jan 31, 2023 | ($183.25M) | Mar 10, 2025 |
| FY2023 | Jan 31, 2022 | ($234.80M) | Mar 7, 2024 |
| FY2022 | Jan 31, 2021 | ($92.63M) | Mar 9, 2023 |
| FY2022 | Jan 31, 2020 | ($141.78M) | Mar 16, 2022 |
| FY2021 | Jan 31, 2019 | ($140.08M) | Mar 18, 2021 |
| FY2020 | Jan 31, 2018 | ($135.49M) | Mar 23, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($293.29M) | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | ($116.40M) | Mar 5, 2026 |
| FY2026 | Jan 31, 2024 | ($19.14M) | Mar 5, 2026 |
| FY2024 | Jan 31, 2023 | ($190.11M) | Mar 10, 2025 |
| FY2023 | Jan 31, 2022 | ($142.55M) | Mar 7, 2024 |
| FY2022 | Jan 31, 2021 | ($92.53M) | Mar 9, 2023 |
| FY2022 | Jan 31, 2020 | ($146.07M) | Mar 16, 2022 |
| FY2021 | Jan 31, 2019 | ($136.86M) | Mar 18, 2021 |
| FY2020 | Jan 31, 2018 | ($131.44M) | Mar 23, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.38B | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | $1.08B | Mar 5, 2026 |
| FY2026 | Jan 31, 2024 | $780.32M | Mar 5, 2026 |
| FY2024 | Jan 31, 2023 | $608.36M | Mar 10, 2025 |
| FY2023 | Jan 31, 2022 | $371.28M | Mar 7, 2024 |
| FY2022 | Jan 31, 2021 | $214.67M | Mar 9, 2023 |
| FY2022 | Jan 31, 2020 | $130.19M | Mar 16, 2022 |
| FY2021 | Jan 31, 2019 | $84.55M | Mar 18, 2021 |
| FY2020 | Jan 31, 2018 | $58.89M | Mar 23, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.61B | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | $1.38B | Mar 5, 2026 |
| FY2026 | Jan 31, 2024 | $1.17B | Mar 5, 2026 |
| FY2024 | Jan 31, 2023 | $941.01M | Mar 10, 2025 |
| FY2023 | Jan 31, 2022 | $574.78M | Mar 7, 2024 |
| FY2022 | Jan 31, 2021 | $356.57M | Mar 9, 2023 |
| FY2022 | Jan 31, 2020 | $99.94M | Mar 16, 2022 |
| FY2021 | Jan 31, 2019 | ($22.97M) | Mar 18, 2021 |
| FY2020 | Jan 31, 2018 | ($58.77M) | Mar 23, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $302.11M | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | $254.85M | Mar 5, 2026 |
| FY2026 | Jan 31, 2024 | $176.53M | Mar 5, 2026 |
| FY2024 | Jan 31, 2023 | $235.02M | Mar 10, 2025 |
| FY2023 | Jan 31, 2022 | $112.14M | Mar 7, 2024 |
| FY2022 | Jan 31, 2021 | $52.80M | Mar 9, 2023 |
| FY2022 | Jan 31, 2020 | $80.20M | Mar 16, 2022 |
| FY2021 | Jan 31, 2019 | $35.85M | Mar 18, 2021 |
| FY2020 | Jan 31, 2018 | $22.91M | Mar 23, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $11.09B | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | $8.70B | Mar 5, 2026 |
| FY2024 | Jan 31, 2024 | $6.65B | Mar 10, 2025 |
| FY2023 | Jan 31, 2023 | $5.03B | Mar 7, 2024 |
| FY2022 | Jan 31, 2022 | $3.62B | Mar 9, 2023 |
| FY2022 | Jan 31, 2021 | $2.73B | Mar 16, 2022 |
| FY2021 | Jan 31, 2020 | $1.40B | Mar 18, 2021 |
| FY2020 | Jan 31, 2019 | $433.22M | Mar 23, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $6.61B | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | $5.38B | Mar 5, 2026 |
| FY2024 | Jan 31, 2024 | $4.31B | Mar 10, 2025 |
| FY2023 | Jan 31, 2023 | $3.54B | Mar 7, 2024 |
| FY2022 | Jan 31, 2022 | $2.58B | Mar 9, 2023 |
| FY2022 | Jan 31, 2021 | $1.86B | Mar 16, 2022 |
| FY2021 | Jan 31, 2020 | $662.30M | Mar 18, 2021 |
| FY2020 | Jan 31, 2019 | $363.10M | Mar 23, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $4.43B | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | $3.28B | Mar 5, 2026 |
| FY2024 | Jan 31, 2024 | $2.30B | Mar 10, 2025 |
| FY2023 | Jan 31, 2023 | $1.46B | Mar 7, 2024 |
| FY2022 | Jan 31, 2022 | $1.03B | Mar 9, 2023 |
| FY2022 | Jan 31, 2021 | $870.57M | Mar 16, 2022 |
| FY2021 | Jan 31, 2020 | $742.11M | Mar 18, 2021 |
| FY2020 | Jan 31, 2019 | ($487.79M) | Mar 23, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.36B | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | $912.81M | Mar 5, 2026 |
| FY2024 | Jan 31, 2024 | $638.04M | Mar 10, 2025 |
| FY2023 | Jan 31, 2023 | $430.65M | Mar 7, 2024 |
| FY2022 | Jan 31, 2022 | $416.45M | Mar 9, 2023 |
| FY2022 | Jan 31, 2021 | $83.57M | Mar 16, 2022 |
| FY2021 | Jan 31, 2020 | $7.72M | Mar 18, 2021 |
| FY2020 | Jan 31, 2019 | $7.95M | Mar 23, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($1.28B) | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | ($1.12B) | Mar 5, 2026 |
| FY2024 | Jan 31, 2024 | ($1.06B) | Mar 10, 2025 |
| FY2023 | Jan 31, 2023 | ($1.15B) | Mar 7, 2024 |
| FY2022 | Jan 31, 2022 | ($964.92M) | Mar 9, 2023 |
| FY2022 | Jan 31, 2021 | ($730.12M) | Mar 16, 2022 |
| FY2021 | Jan 31, 2020 | ($637.49M) | Mar 18, 2021 |
| FY2020 | Feb 1, 2019 | ($495.71M) | Mar 23, 2020 |
| FY2020 | Jan 31, 2019 | ($519.13M) | Mar 23, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $5.23B | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | $4.32B | Mar 5, 2026 |
| FY2026 | Jan 31, 2024 | $3.38B | Mar 5, 2026 |
| FY2024 | Jan 31, 2023 | $2.46B | Mar 10, 2025 |
| FY2023 | Jan 31, 2022 | $2.00B | Mar 7, 2024 |
| FY2022 | Jan 31, 2021 | $1.92B | Mar 9, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 0 | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | 0 | Mar 5, 2026 |
| FY2026 | Jan 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Jan 31, 2023 | 0 | Mar 10, 2025 |
| FY2023 | Jan 31, 2022 | (1) | Mar 7, 2024 |
| FY2022 | Jan 31, 2021 | 0 | Mar 9, 2023 |
| FY2022 | Jan 31, 2020 | 0 | Mar 16, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 0 | Mar 5, 2026 |
| FY2026 | Jan 31, 2025 | 0 | Mar 5, 2026 |
| FY2026 | Jan 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Jan 31, 2023 | 0 | Mar 10, 2025 |
| FY2023 | Jan 31, 2022 | (1) | Mar 7, 2024 |
| FY2022 | Jan 31, 2021 | 0 | Mar 9, 2023 |
| FY2022 | Jan 31, 2020 | 0 | Mar 16, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jan 31, 2020 | 0 | Mar 23, 2020 |
| FY2020 | Jan 31, 2019 | 47.42M | Mar 23, 2020 |